Recent Updates
Recently added Catalysts
MNKD Positive Sentiment

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Key Takeaway: MannKind Corporation will release its third quarter 2025 financial results on November 5, 2025, before the market opens. A webcast will follow at 9 a.m. ET to discuss the results and provide a business update. The company focuses on innovative treatments for chronic diseases, including diabetes and pulmonary hypertension.
Price reaction · baseline $5.54 (2025-10-29 close) · hit after-hours · clean, no other MNKD news in the window
day 0 close · peak
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • MannKind is actively engaging with investors through a conference call.
  • The company is focused on addressing serious unmet medical needs.
  • MannKind's innovative approach aims to transform chronic disease care.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.2%
average across 10 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Technosphere Insulin
Phase 1 · Healthy Volunteers

Full Press Release Details

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) --MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2025 financial results will be released before the market opens on November 5, 2025.
MannKind will host a webcast beginning at 9 a.m. Eastern Time to discuss the financial results and provide a business update. The webcast will be accessible via a link on MannKind’s website athttps://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKindMannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more atmannkindcorp.com.

Frequently Asked Questions

When will MannKind release its Q3 2025 financial results?

MannKind will release its Q3 2025 financial results on November 5, 2025.

What time is the MannKind conference call?

The MannKind conference call will begin at 9 a.m. Eastern Time.

How can I access the MannKind webcast?

The webcast can be accessed via MannKind's investor website.

What is MannKind's focus in biopharmaceuticals?

MannKind focuses on innovative treatments for chronic diseases like diabetes.

Last updated: Oct 29, 2025